DDInter1268 DDInter1376
Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA reintroduced the drug to the market for multiple sclerosis. Natalizumab was further approved by the FDA for the treatment of Crohn's Disease in January 2008. On August 24, 2023, the first biosimilar to natalizumab, natalizumab-sztn, was approved by the FDA. Natalizumab was approved by the European Commission on September 22, 2023.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Natalizumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc sulfate
Natalizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clostridium tetani toxoid antigen (formaldehyde inactivated)
Natalizumab {u} may lead to a major life threatening interaction when taken with {v} Certolizumab pegol
Natalizumab {u} may lead to a major life threatening interaction when taken with {v} Muromonab
Natalizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Natalizumab may lead to a major life threatening interaction when taken with Certolizumab pegol
Natalizumab may lead to a major life threatening interaction when taken with Muromonab